Indacaterol (BioDeep_00000615045)

   


代谢物信息卡片


5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one

化学式: C24H28N2O3 (392.20998180000004)
中文名称: 茚达特罗
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
InChI: InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1

描述信息

R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research[1][2].

同义名列表

2 个代谢物同义名

Indacaterol; 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Cui Tang, Chen-Xi Ou-Yang, Wen-Jing Chen, Chan Zou, Jie Huang, Chang Cui, Shuang Yang, Can Guo, Xiao-Yan Yang, Yu Lin, Qi Pei, Guo-Ping Yang. Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2022 Jan; 168(?):106055. doi: 10.1016/j.ejps.2021.106055. [PMID: 34742834]
  • Meng-Jer Hsieh, Ning-Hung Chen, Shih-Lung Cheng, Chi-Wei Tao, Yu-Feng Wei, Yao-Kuang Wu, Ming-Cheng Chan, Shih-Feng Liu, Wu-Huei Hsu, Tsung-Ming Yang, Ming-Shian Lin, Ching-Lung Liu, Ping-Hung Kuo, Ying-Huang Tsai. Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study. International journal of chronic obstructive pulmonary disease. 2022; 17(?):967-976. doi: 10.2147/copd.s353799. [PMID: 35510163]
  • Soniya Vaidya, Juergen Jauernig, Brian Ethell, Nasri Abdallah, Surendra Machineni, Anton Drollmann, Olivier Heudi, Stefanie Last, Michael Hahn, Rajkumar Radhakrishnan, Stanislav Ignatenko, Hanns-Christian Tillmann. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. Pulmonary pharmacology & therapeutics. 2020 10; 64(?):101964. doi: 10.1016/j.pupt.2020.101964. [PMID: 33035700]
  • Chan Zou, Qian Yang, Shuang Yang, Xingfei Zhang, Xiaoyan Yang, Zhijun Huang, Qi Pei, Jie Huang, Guoping Yang. Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration. Pulmonary pharmacology & therapeutics. 2020 04; 61(?):101902. doi: 10.1016/j.pupt.2020.101902. [PMID: 32045673]
  • Francesco Spannella, Federico Giulietti, Valentina Cesari, Antonio Francioso, Guido Cocci, Laura Landi, Francesca Elena Lombardi, Elisabetta Borioni, Beatrice Bernardi, Giulia Rosettani, Valentina Bordoni, Corrado Iacoacci, Piero Giordano, Riccardo Sarzani. Combination Therapy of Inhaled Indacaterol/Glycopyrronium for Chronic Obstructive Pulmonary Disease in the Very Elderly: Is It Safe? An Electrocardiographic Evaluation. Respiration; international review of thoracic diseases. 2018 ; 95 Suppl 1(?):22-29. doi: 10.1159/000487182. [PMID: 29705783]
  • Si Yan, Duncan E Shaw, Linhong Yang, David A Sandham, Mark P Healy, John Reilly, Bing Wang. Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. Journal of medicinal chemistry. 2017 08; 60(16):6867-6879. doi: 10.1021/acs.jmedchem.7b00205. [PMID: 28703592]
  • Wesam G Ammari, Zainab Al-Qadhi, Mohammad Khalil, Rabab Tayyem, Samir Qammaz, Ghaleb Oriquat, Iman A Basheti, Henry Chrystyn. Indacaterol determination in human urine: validation of a liquid-liquid extraction and liquid chromatography-tandem mass spectrometry analytical method. Journal of aerosol medicine and pulmonary drug delivery. 2015 Jun; 28(3):202-10. doi: 10.1089/jamp.2014.1153. [PMID: 25229261]
  • Mario Cazzola, Luigino Calzetta, Clive P Page, Maria Gabriella Matera. Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert opinion on drug metabolism & toxicology. 2014 Jan; 10(1):129-37. doi: 10.1517/17425255.2014.865723. [PMID: 24295085]
  • Cho-Ming Loi, Dennis A Smith, Deepak Dalvie. Which metabolites circulate?. Drug metabolism and disposition: the biological fate of chemicals. 2013 May; 41(5):933-51. doi: 10.1124/dmd.112.050278. [PMID: 23454828]
  • Mark Kagan, Jeremy Dain, Lana Peng, Christine Reynolds. Metabolism and pharmacokinetics of indacaterol in humans. Drug metabolism and disposition: the biological fate of chemicals. 2012 Sep; 40(9):1712-22. doi: 10.1124/dmd.112.046151. [PMID: 22648561]
  • Soichiro Matsushima, Ivan Matthews, Ralph Woessner, Gregory Pinault, Hisanori Hara, Justin Wilkins, Kaneo Sekiguchi. Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations. International journal of clinical pharmacology and therapeutics. 2012 Aug; 50(8):545-56. doi: 10.5414/cp201719. [PMID: 22735463]
  • Corinne Emotte, Olivier Heudi, Fanny Deglave, Adrien Bonvie, Laurence Masson, Franck Picard, Animesh Chaturvedi, Tapan Majumdar, Ashish Agarwal, Ralph Woessner, Olivier Kretz. Validation of an on-line solid-phase extraction method coupled to liquid chromatography-tandem mass spectrometry detection for the determination of Indacaterol in human serum. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 May; 895-896(?):1-9. doi: 10.1016/j.jchromb.2012.02.025. [PMID: 22483398]
  • Catherine E Morris, Pierre-Alexandre Boucher, Béla Joós. Left-shifted nav channels in injured bilayer: primary targets for neuroprotective nav antagonists?. Frontiers in pharmacology. 2012; 3(?):19. doi: 10.3389/fphar.2012.00019. [PMID: 22375118]
  • Pia Marie Albano, John Donnie A Ramos. Association of house dust mite-specific IgE with asthma control, medications and household pets. Asia Pacific allergy. 2011 Oct; 1(3):145-51. doi: 10.5415/apallergy.2011.1.3.145. [PMID: 22053311]
  • Kenneth R Chapman, Stephen I Rennard, Angeli Dogra, Roger Owen, Cheryl Lassen, Benjamin Kramer. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011 Jul; 140(1):68-75. doi: 10.1378/chest.10-1830. [PMID: 21349928]
  • S Pascoe, C Reynolds, W Pleskow, S Perry, A Hmissi, G Kaiser, L Brookman. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. International journal of clinical pharmacology and therapeutics. 2011 Feb; 49(2):153-61. doi: 10.5414/cpp49153. [PMID: 21255532]
  • James F Donohue, Dave Singh, Oliver Kornmann, David Lawrence, Cheryl Lassen, Benjamin Kramer. Safety of indacaterol in the treatment of patients with COPD. International journal of chronic obstructive pulmonary disease. 2011; 6(?):477-92. doi: 10.2147/copd.s23816. [PMID: 22003293]
  • Motoi Hosoe, Ralph Woessner, Soichiro Matsushima, David Lawrence, Benjamin Kramer. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies. Clinical drug investigation. 2011; 31(4):247-55. doi: 10.2165/11586520-000000000-00000. [PMID: 21184620]
  • Elizabeth M Rosethorne, Robert J Turner, Robin A Fairhurst, Steven J Charlton. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn-Schmiedeberg's archives of pharmacology. 2010 Sep; 382(3):255-63. doi: 10.1007/s00210-010-0533-6. [PMID: 20694793]
  • James F Donohue, Charles Fogarty, Jan Lötvall, Donald A Mahler, Heinrich Worth, Arzu Yorgancioglu, Amir Iqbal, James Swales, Roger Owen, Mark Higgins, Benjamin Kramer. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American journal of respiratory and critical care medicine. 2010 Jul; 182(2):155-62. doi: 10.1164/rccm.200910-1500oc. [PMID: 20463178]
  • Gregory Feldman, Thomas Siler, Niyati Prasad, Damon Jack, Simon Piggott, Roger Owen, Mark Higgins, Benjamin Kramer. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC pulmonary medicine. 2010 Mar; 10(?):11. doi: 10.1186/1471-2466-10-11. [PMID: 20211002]
  • Dario Lombardi, Bernard Cuenoud, Stefanie D Krämer. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2009 Dec; 38(5):533-47. doi: 10.1016/j.ejps.2009.10.001. [PMID: 19819331]
  • Craig LaForce, Phillip Korenblat, Pamela Osborne, Fang Dong, Mark Higgins. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Current medical research and opinion. 2009 Oct; 25(10):2353-9. doi: 10.1185/03007990903143143. [PMID: 19650753]
  • Olivier Bauwens, Vincent Ninane, Boudewijn Van de Maele, Roz Firth, Fang Dong, Roger Owen, Mark Higgins. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Current medical research and opinion. 2009 Feb; 25(2):463-70. doi: 10.1185/03007990802675096. [PMID: 19192991]
  • Jutta Beier, Pascal Chanez, Jean-Benoit Martinot, A J M Schreurs, Ruzena Tkácová, Weibin Bao, Damon Jack, Mark Higgins. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulmonary pharmacology & therapeutics. 2007; 20(6):740-9. doi: 10.1016/j.pupt.2006.09.001. [PMID: 17088091]
  • J H Youson. Absorption and transport of exogenous protein in the archinephric duct of the opisthonephric kidney of the sea lamprey, Petromyzon marinus L. Comparative biochemistry and physiology. A, Comparative physiology. 1975 Dec; 52(4):639-43. doi: 10.1016/s0300-9629(75)80016-8. [PMID: 1189]